Low-Intensity DOACs in VTE: Sapienza University Reports Long-Term Outcomes
Friends of Mediterranean Journal of Hematology and Infectious Diseases Group shared a post by on LinkedIn:
“Direct oral anticoagulants (DOACs) are widely used for the treatment and secondary prophylaxis of venous thromboembolism (VTE).
Nowadays, DOACs represent the gold standard for long-term anticoagulation, with low-intensity DOAC administration becoming increasingly used worldwide in such scenarios.
Although low-intensity apixaban and rivaroxaban are approved for clinical usage as secondary VTE prophylaxis, there is limited literature regarding their efficacy and safety with a long follow-up.
Here we report the long experience of Sapienza University in Rome.”
Read the full article here.
Article: Secondary Prophylaxis of Venous Thromboembolism (VTE) with low dose Apixaban or Rivaroxaban: Results from a patient population with more than 2 years of median follow-up
Authors: Alessandro Laganà, Giovanni Manfredi Assanto, Chiara Masucci, Mauro Passucci, Livia Donzelli, Alessandra Serrao, Erminia Baldacci, Cristina Santoro, Antonio Chistolini
Stay updated on the latest scientific advances in the field of thrombosis with Hemostasis Today.
-
Jul 9, 2026, 08:46Jordan Agay: Folate Deficiency in Patients Receiving PARP Inhibitors
-
Jul 9, 2026, 08:29Laura Katz: Is Human Lactoferrin Better Than Bovine Lactoferrin?
-
Jul 9, 2026, 08:17Anziya Sabeer: AI-Driven Non-Invasive Anemia Detection
-
Jul 9, 2026, 07:37Variable Mechanisms of ADAMTS13 Inhibition by Autoantibodies in iTTP – JTH
-
Jul 9, 2026, 07:31DHR-Sponsored Training Programme at ICMR-CRMCH Week 2 – Day 4 – ICMR-NIRBID
-
Jul 9, 2026, 06:03Barbara Adams Krolak: ISTH Launches Global Women’s Health Hub
-
Jul 9, 2026, 05:49Abdul Mannan: A Low Platelet Count is not Always a Bone Marrow Problem
-
Jul 9, 2026, 05:41Julieta Rosales: Management of Tandem Strokes – To Stent or Not to Stent?
-
Jul 8, 2026, 21:30Matthew Gouveia: How VNS-REHAB Is Transforming the Future of Stroke Rehabilitation